G. Mcfarlane

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

G. Krishnamurthy, M. Abou-Gharbia, H. Elokdah, 2004, Journal of medicinal chemistry.

Regioselective Suzuki coupling of benzofuran or benzothiophene boronic acids and dibromo substituted naphthalenes: synthesis of a potent inhibitor of plasminogen activator inhibitor-1

H. Elokdah, Z. Wang, G. Mcfarlane, 2006 .

SAM-531, N,N-dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy} propan-1-amine, a novel serotonin-6 receptor antagonist with preclinical pro-cognitive efficacy

T. Comery, A. Robichaud, M. Pangalos, 2010, Alzheimer's & Dementia.

Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.

A. Robichaud, R. Magolda, H. Elokdah, 2007, Bioorganic & medicinal chemistry.

Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties.

M. Abou-Gharbia, H. Elokdah, M. McKean, 2004, Journal of medicinal chemistry.

Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 2. Selective and potent benzylamino cyclobutenediones.

A. Gilbert, G. Francisco, T. Argentieri, 2000, Journal of medicinal chemistry.

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.

K. Marquis, S. Grauer, J. Brennan, 2009, Bioorganic & medicinal chemistry letters.